Marginal zone B-cell lymphoma of the conjunctiva

Expert Review of Ophthalmology

Volumn 5, Issue 2, 2010, Pages 177-188

  Ferreri, Andrés J M ^a   Govi, Silvia ^a   Resti, Antonio Giordano ^a   Modorati, Giulio ^a   Dolcetti, Riccardo ^a   Colucci, Annalisa ^a  

^a NONE

Author keywords

Chlamydophila psittaci; Conjunctival MALT lymphoma; MALT; Rituximab

Indexed keywords

ALPHA INTERFERON; CHLORAMBUCIL; DOXYCYCLINE; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; MITOMYCIN C; RITUXIMAB;

AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BLOOD ANALYSIS; BONE MARROW BIOPSY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CARCINOGENESIS; CATARACT; CHEMOSIS; CHLAMYDOPHILA PSITTACI; CHROMOSOME ABERRATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONJUNCTIVA LYMPHOMA; CORNEA ULCER; CYTOPENIA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRY EYE; EXTERNAL BEAM RADIOTHERAPY; EYE SURGERY; FLU LIKE SYNDROME; GENE MUTATION; HUMAN; KERATITIS; MARGINAL ZONE LYMPHOMA; MOLECULAR BIOLOGY; ORNITHOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; WATCHFUL WAITING;

EID: 77951630141     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.10.11     Document Type: Review

References (97)

1. Margo CE, Mulla ZD. Malignant tumors of the orbit. Analysis of the Florida Cancer Registry. Ophthalmology 105(1), 185-190 (1998).
2. Decaudin D, de Cremoux P, Vincent-Salomon A, Dendale R, Rouic LL. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood 108(5), 1451-1460 (2006).
3. Sasai K, Yamabe H, Dodo Y, Kashii S, Nagata Y, Hiraoka M Non-Hodgkin's Lymphoma of the Ocular Adnexa. Acta Oncol. 40(4), 485-490 (2001).
4. Moslehi R, Devesa SS, Schairer C, Fraumeni JF Jr. Rapidly increasing incidence of ocular non-Hodgkin lymphoma. J. Natl Cancer Inst. 98(13), 936-939 (2006).
5. Coupland SE, Jaehne D, Hummel M, Stein H. The tale and molecular trail of a disseminated ocular adnexal malt lymphoma. Graefes Arch. Clin. Exp. Ophthalmol. 245(7), 1055-1059 (2007).
6. Knowles DM, Jakobiec FA, McNally L, Burke JS. Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids), a prospective multiparametric ana lysis of 108 cases during 1977 to 1987. Hum. Pathol. 21(9), 959-973 (1990).
7. Meunier J, Lumbroso-Le Rouic L, Vincent-Salomon A et al. Ophthalmologic and intraocular non-Hodgkins lymphoma, a large single centre study of initial characteristics, natural history, and prognostic factors. Hematol. Oncol. 22(4), 143-158 (2004).
8. Bardenstein DS. Ocular adnexal lymphoma: classifcation, clinical disease, and molecular biology. Ophthalmol. Clin. North Am. 18(1), 187-197 (2005).
9. Hatef E, Roberts D, McLaughlin P, Pro B, Esmaeli B. Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. Arch. Ophthalmol. 125(12), 1663-1667 (2007).
10. Lagoo AS, Haggerty C, Kim Y et al. Morphologic features of 115 lymphomas of the orbit and ocular adnexa categorized according to the World Health Organization classifcation, are marginal zone lymphomas in the orbit mucosa-associated lymphoid tissue-type lymphomas? Arch. Pathol. Lab. Med. 132(9), 1405-1416 (2008).
11. Ferreri AJ, Dognini GP, Ponzoni M et al. Chlamydia-psittaci-eradicating antibiotic therapy in patients with advanced-stage ocular adnexal MALT lymphoma. Ann. Oncol. 19(1), 194-195 (2008).
12. Mannami T, Yoshino T, Oshima K et al. Clinical, histopathological, and immunogenetic ana lysis of ocular adnexal lymphoproliferative disorders: characterization of malt lymphoma and reactive lymphoid hyperplasia. Mod. Pathol. 14(7), 641-649 (2001).
13. Coupland SE, Foss HD, Anagnostopoulos I, Hummel M, Stein H. Immunoglobulin VH gene expression among extranodal marginal zone B-cell lymphomas of the ocular adnexa. Invest. Ophthalmol. Vis. Sci. 40(3), 555-562 (1999).
14. Hara Y, Nakamura N, Kuze T et al. Immunoglobulin heavy chain gene ana lysis of ocular adnexal extranodal marginal zone B-cell lymphoma. Invest. Ophthalmol. Vis. Sci. 42(11), 2450-2457 (2001).
15. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS. Strong expression of FOXP1 identifes a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 104(9), 2933-2935 (2004).
16. Remstein ED, Kurtin PJ, James CD, Wang XY, Meyer RG, Dewald GW. Mucosa-associated lymphoid tissue lymphomas with t(11; 18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways. Am. J. Pathol. 161(1), 63-71 (2002).
17. Streubel B, Simonitsch-Klupp I, Mullauer L et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 18(10), 1722-1726 (2004).
18. Tanimoto K, Sekiguchi N, Yokota Y et al. Fluorescence in situ hybridization (FISH) ana lysis of primary ocular adnexal MALT lymphoma. BMC Cancer 6,249 (2006).
19. Ott G, Katzenberger T, Greiner A et al The t(11;18)(q21;q21) Chromosome Translocation Is A Frequent and Specifc Aberration in Low-grade but Not High-grade Malignant Non-Hodgkin's Lymphomas of the Mucosa-associated Lymphoid Tissue (MALT-) Type. Cancer Res. 57(18), 3944-3948 (1997)
20. Raderer M, Wohrer S, Streubel B et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J. Clin. Oncol. 24(19), 3136-3141 (2006).
21. Ruiz A, Reischl U, Swerdlow SH et al. Extranodal marginal zone B-cell lymphomas of the ocular adnexa: multiparameter ana lysis of 34 cases including interphase molecular cytogenetics and PCR for Chlamydia psittaci. Am. J. Surg. Pathol. 31(5), 792-802 (2007).
22. Matteucci C, Galieni P, Leoncini L et al. Typical genomic imbalances in primary MALT lymphoma of the orbit. J. Pathol. 200(5), 656-660 (2003).
23. Zhou Y, Ye H, Martin-Subero JI et al. Distinct comparative genomic hybridisation profles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21). Br. J. Haematol. 133(1), 35-42 (2006).
24. Knop N, Knop E. Conjunctiva-associated lymphoid tissue in the human eye. Invest. Ophthalmol. Vis. Sci. 41(6), 1270-1279 (2000).
25. Mondal SK. Mucosa-asso ciated lymphoid tissue lymphoma in conjunctiva. Indian J. Pathol. Microbiol. 51(3), 407-408 (2008).
26. Sjo LD Ophthalmic Lymphoma: Epidemiology and Pathogenesis. Acta Ophthalmol. 87(Thesis 1), 1-20 (2009).
27. Secchiero P, Lamberti G, Corallini F et al. Conjunctival sac fuid contains elevated levels of soluble TRAIL: implications for the anti-tumoral surveillance of the anterior surface of the eye. J. Cell Physiol. 218(1), 199-204 (2009).
28. Du MQ, Isaccson PG Gastric MALT Lymphoma: From Aetiology to Treatment. Lancet Oncol. 3(2), 97-104 (2002).
29. Moslehi R, Devesa SS, Schairer C, Fraumeni JF Jr. Rapidly increasing incidence of ocular non-Hodgkin lymphoma. J. Natl Cancer Inst. 98(13), 936-939 (2006).
30. Pascual V, Capra JD. VH4-21, a human VH gene segment over represented in the autoimmune repertoire. Arthritis Rheum. 35(1), 11-18 (1992).
31. Bahler DW, Campbell MJ, Hart S, Miller RA, Levy S, Levy R. Ig VH gene expression among human follicular lymphomas. Blood 78(6), 1561-1568 (1991).
32. Bahler DW, Szankasi P, Kulkarni S, Tubbs RR, Cook JR, Swerdlow SH. Use of similar immunoglobulin VH gene segments by MALT lymphomas of the ocular adnexa. Mod. Pathol. 22(6), 833-838 (2009).
33. Ferreri AJ, Guidoboni M, Ponzoni M et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J. Natl Cancer Inst. 96(8), 586-594 (2004).
34. Byrne GI, Ojcius DM. Chlamydia and apoptosis: life and death decisions of an intracellular pathogen. Nat. Rev. Microbiol. 2(10), 802-808 (2004).
35. Smith JS, Munoz N, Herrero R et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J. Infect. Dis. 185(3), 324-331 (2002).
36. Miyairi I, Byrne GI. Chlamydia and programmed cell death. Curr. Opin. Microbiol. 9(1), 102-108 (2006).
37. Ferreri AJ, Dolcetti R, Dognini GP et al. Chlamydophila psittaci is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: results of a single-center prospective case-control study. Int. J. Cancer 123, 1089-1093 (2008).
38. Yeung L, Tsao YP, Chen PY, Kuo TT, Lin KK, Lai LJ. Combination of adult inclusion conjunctivitis and mucosa-associated lymphoid tissue (MALT) lymphoma in a young adult. Cornea 23(1), 71-75 (2004).
39. Oldstone MB Molecular Mimicry and Immune-mediated Diseases. FASEB J. 12(13), 1255-1265 (1998).
40. Negrini R, Savio A, Poiesi C et al. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology 111(3), 655-665 (1996).
41. Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: a role for heat shock proteins in immunisation. Atherosclerosis 167(2), 177-185 (2003).
42. Pockley AG. Heat shock proteins as regulators of the immune response. Lancet 362(9382), 469-476 (2003).
43. Ishii E, Yokota K, Sugiyama T et al. Immunoglobulin G1 antibody response to Helicobacter pylori heat shock protein 60 is closely associated with low-grade gastric mucosa-associated lymphoid tissue lymphoma. Clin. Diagn. Lab. Immunol. 8(6), 1056-1059 (2001).
44. Decaudin D, Dolcetti R, de Cremoux P et al. Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas, methodological biases or true geographical variations? Anticancer Drugs 19(8), 761-765 (2008).
45. Chanudet E, Zhou Y, Bacon CM et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J. Pathol. 209(3), 344-351 (2006).
46. Ferreri AJ, Ponzoni M, Guidoboni M et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J. Natl Cancer Inst. 98(19), 1375-1382 (2006). (Pubitemid 44530714)
47. Matthews JM, Moreno LI, Dennis J et al. Ocular adnexal lymphoma: no evidence for bacterial DNA associated with lymphoma pathogenesis. Br. J. Haematol. 142(2), 246-249 (2008).
48. Ponzoni M, Ferreri AJ, Guidoboni M et al. Chlamydia infection and lymphomas, association beyond ocular adnexal lymphomas highlighted by multiple detection methods. Clin. Cancer Res. 14(18), 5794-5800 (2008).
49. Chan CC, Shen D, Mochizuki M et al. Detection of Helicobacter pylori and Chlamydia pneumoniae genes in primary orbital lymphoma. Trans. Am. Ophthalmol. Soc. 104, 62-70 (2006).
50. Ferreri AJ, Ponzoni M, Viale E et al. Association between Helicobacter pylori infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications. Hematol. Oncol. 24(1), 33-37 (2006).
51. Sjo NC, Foegh P, Juhl BR et al. Role of Helicobacter pylori in conjunctival mucosa-associated lymphoid tissue lymphoma. Ophthalmology 114(1), 182-186 (2007).
52. Lee SB, Yang JW, Kim CS. The association between conjunctival MALT lymphoma and Helicobacter pylori. Br. J. Ophthalmol. 92(4), 534-536 (2008).
53. Goebel N, Serr A, Mittelviefhaus H, Reinhard T, Bogdan C, Auw-Haedrich C. Chlamydia psittaci, Helicobacter pylori and ocular adnexal lymphoma-is there an association? The German experience. Leuk. Res. 31(10), 1450-1452 (2007).
54. Cohen VM, Sweetenham J, Singh AD. Ocular adnexal lymphoma. What is the evidence for an infectious aetiology? Br. J. Ophthalmol. 92(4), 446-448 (2008).
55. Arnaud P, Escande MC, Lecuit M et al. Hepatitis C virus infection and MALT-type ocular adnexal lymphoma. Ann. Oncol. 18(2), 400-401 (2007).
56. Ferreri AJ, Viale E, Guidoboni M et al. Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann. Oncol. 17(5), 769-772 (2006).
57. Arcaini L, Burcheri S, Rossi A et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann. Oncol. 18(2), 346-350 (2006).
58. Bhatia S, Paulino AC, Buatti JM, Mayr NA, Wen BC. Curative radiotherapy for primary orbital lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 54(3), 818-823 (2002).
59. Martinet S, Ozsahin M, Belkacemi Y et al. Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 55(4), 892-898 (2003).
60. Uno T, Isobe K, Shikama N et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. Cancer 98(4), 865-871 (2003).
61. Rosado MF, Byrne JG, Ding F et al. Ocular adnexal lymphoma: a clinicopathological study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood 107(2), 467-472 (2005).
62. Fung CY, Tarbell NJ, Lucarelli MJ et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classifcation subtypes. Int. J. Radiat. Oncol. Biol. Phys. 57(5), 1382-1391 (2003).
63. Nutting CM, Shah-Desai S, Rose GE, Norton AP, Plowman PN. Thyroid orbitopathy possibly predisposes to late-onset of periocular lymphoma. Eye 20(6), 645-648 (2006).
64. Raderer M, Osterreicher C, Machold K et al. Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. Ann. Oncol. 12(7), 937-939 (2001).
65. Raderer M, Wohrer S, Streubel B et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J. Clin. Oncol. 24(19), 3136-3141 (2006).
66. Coupland SE, White VA, Rootman J, Damato B, Finger PT A TNM-based clinical staging system of ocular adnexal lymphomas. Arch. Pathol. Lab. Med. 133(8), 1262-1267 (2009).
67. Ferreri AJ, Dolcetti R, Du MQ et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Ann. Oncol. 19(5), 835-846 (2008).
68. Fung CY, Tarbell NJ, Lucarelli MJ et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classifcation subtypes. Int. J. Radiat. Oncol. Biol. Phys. 57(5), 1382-1391 (2003).
69. Meunier J, Lumbroso-Le Rouic L, Dendale R et al. Conjunctival low-grade non-Hodgkin's lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors. Leuk. Lymphom. 47(7), 1295-1305 (2006).
70. Ejima Y, Sasaki R, Okamoto Y et al. Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Radiother. Oncol. 78(1), 6-9 (2006).
71. Tsang RW, Gospodarowicz MK, Pintilie M et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J. Clin. Oncol. 21(22), 4157-4164 (2003).
72. Ben Simon GJ, Cheung N, McKelvie P, Fox R, McNab AA. Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology 113(7), 1209-1213 (2006).
73. Liu YX, Yoshino T, Ohara N et al. Loss of expression of a4b7 integrin and L-selectin is associated with high-grade progression of low-grade MALT lymphoma. Mod. Pathol. 14(8), 798-805 (2001).
74. Falkenhagen KM, Braziel RM, Fraunfelder FW, Smith JR. B-cells in ocular adnexal lymphoproliferative lesions express B-cell attracting chemokine 1 (CXCL13). Am. J. Ophthalmol. 140(2), 335-337 (2005).
75. Tanimoto K, Kaneko A, Suzuki S et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann. Oncol. 17(1), 135-140 (2006).
76. Uno T, Isobe K, Shikama N et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. Cancer 98(4), 865-871 (2003).
77. Bolek TW, Moyses HM, Marcus RB Jr et al. Radiotherapy in the management of orbital lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 44(1), 31-36 (1999).
78. Bhatia S, Paulino AC, Buatti JM, Mayr NA, Wen BC. Curative radiotherapy for primary orbital lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 54(3), 818-823 (2002).
79. Tomita N, Kodaira T, Tachibana H, Nakamura T, Mizoguchi N, Takada A. Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma. Radiother. Oncol. 90(2), 231-235 (2009).
80. Regueiro CA, Valcarcel FJ, Romero J, de la Torre A. Treatment of conjunctival lymphomas by b-ray brachytherapy using a strontium-90-yttrium-90 applicator. Clin. Oncol. (R. Coll. Radiol.) 14(6), 459-463 (2002).
81. Abramson DH, Rollins I, Coleman M. Periocular mucosa-associated lymphoid/low grade lymphomas: treatment with antibiotics. Am. J. Ophthalmol. 140(4), 729-730 (2005).
82. Ferreri AJ, Dolcetti R, Magnino S et al. A woman and her canary: a tale of Chlamydiae and lymphomas. J. Natl Cancer Inst. 99(18), 1418-1419 (2007).
83. Grunberger B, Wohrer S, Streubel B et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J. Clin. Oncol. 24(9), 1370-1375 (2006). (Pubitemid 46622000)
84. Greco G, Corrente M, Martella V. Detection of Chlamydophila psittaci in asymptomatic animals. J. Clin. Microbiol. 43(10), 5410-5411 (2005).
85. Matsuo T, Yoshino T. Long-term follow-up results of observation or radiation for conjunctival malignant lymphoma. Ophthalmology 111(6), 1233-1237 (2004).
86. Matsuo T, Ichimura K, Yoshino T. Spontaneous regression of bilateral conjunctival extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. J. Clin. Exp. Hematop. 47(2), 79-81 (2007).
87. Ferreri AJ, Dognini GP, Crocchiolo R et al. A six-month regimen of oral clarithromycin is a feasible and active therapy for patients with relapsed/refractory marginal zone B-cell lymphoma of MALT-type. Blood 112, 3062 (2008).
88. Ferreri AJ, Ponzoni M, Martinelli G et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica 90(11), 1578-1579 (2005).
89. Rigacci L, Nassi L, Puccioni M et al. Rituximab and chlorambucil as frst-line treatment for low-grade ocular adnexal lymphomas. Ann. Hematol. 86(8), 565-568 (2007).
90. Salepci T, Seker M, Kurnaz E et al. Conjunctival malt lymphoma successfully treated with single agent rituximab therapy. Leuk. Res. 33(3), e10-e13 (2009).
91. Nuckel H, Meller D, Steuhl K P, Duhrsen U. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. Eur. J. Haematol. 73(4), 258-262 (2004).
92. Esmaeli B, Murray JL, Ahmadi MA et al. Immunotherapy for low-grade non-Hodgkin secondary lymphoma of the orbit. Arch. Ophthalmol. 120(9), 1225-1227 (2002).
93. Esmaeli B, McLaughlin P, Pro B et al. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann. Oncol. 20(4), 709-714 (2009).
94. Blasi MA, Gherlinzoni F, Calvisi G et al. Local chemotherapy with interferon-a for conjunctival mucosa-associated lymphoid tissue lymphoma: a preliminary report. Ophthalmology 108(3), 559-562 (2001).
95. Lachapelle KR, Rathee R, Kratky V, Dexter DF. Treatment of conjunctival mucosa-associated lymphoid tissue lymphoma with intralesional injection of interferon a-2b. Arch. Ophthalmol. 118(2), 284-285 (2000).
96. Yu CS, Chiu SI, Ng CS, Chan HH, Tse RK. Localized conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma is amenable to local chemotherapy. Int. Ophthalmol. 28(1), 51-54 (2008).
97. Govi S, Colucci C, Crocchiolo R, Modorati G, Ferreri AJ. Intralesional rituximab is a new safe and active treatment in conjunctival lymphomas. Haematologica 94(Suppl. 3), P251 (2009).